Search the Newsreel

NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed?

NeoGenomics recently finalized a civil settlement with the U.S. Department of Justice for nearly $10 million, resolving a compliance overhang after an internal investigation into past agreements. Despite a 7.7% stock drop, the settlement amount is manageable given prior reserves, and the company is …

NeoGenomics | 10-Q: Q2 2026 Earnings Report

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NeoGenomics (NASDAQ:NEO) reported strong Q2 CY2026 results, exceeding Wall Street's expectations for revenue and adjusted EPS. The oncology diagnostics company's revenue grew 11.2% year-on-year to $201.7 million, with an adjusted EPS of $0.05. NeoGenomics also slightly raised its full-year revenue and adjusted EPS guidance, …

NEOGENOMICS ($NEO) Releases Q2 2026 Earnings, Stock Rises

NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals

NeoGenomics Laboratories has agreed to pay nearly $10 million to settle allegations that it violated the False Claims Act. The settlement comes after NeoGenomics self-disclosed providing below-market-value consulting services to healthcare providers who referred patients for laboratory testing and paying variable referral-based compensation to …

First Light Asset Management LLC Has $72.20 Million Position in NeoGenomics, Inc. $NEO

First Light Asset Management LLC slightly reduced its stake in NeoGenomics, Inc. by 3% in Q1, but it remains its third-largest position, valued at $72.2 million. NeoGenomics, a cancer-focused genetic testing provider, reported strong Q1 revenue growth of 11.3% year-over-year but remains unprofitable. Analyst …

Bionano Genomics Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast

Bionano Genomics, Inc. has announced it will host a conference call and live webcast on August 10, 2026, at 4:30 p.m. Eastern Time. The purpose of the call is to discuss the company's financial results for the second quarter of 2026 and provide updates …

BNGO|Bionano Genomics Inc|Price:1.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Bionano Genomics Inc (BNGO) by TradingKey, detailing its financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment. It highlights the company's significant growth potential, relatively stable fundamentals, and a "Buy" rating from multiple …

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Genomics, Inc. (Nasdaq: BNGO) has announced that it will hold a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. ET. The event will cover the company's financial results for the second quarter of 2026 and highlight recent corporate …

Bionano Genomics Inc (BNGO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Bionano Genomics Inc (BNGO), allowing investors to evaluate its financial health. It includes operating, investing, and financing cash flow data, with analysis of year-over-year changes and definitions of key financial metrics. The …

NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350

This article provides an overview of Neogenomics Inc (NEO) stock performance and basic financial information. It shows the current stock price, market cap, and a note that a stock score is unavailable due to insufficient data. The article also mentions various sections like Financials, …

NEO Income Statement

This article from TradingKey provides an overview of Neogenomics Inc.'s (NEOUSD) income statement. It explains how to interpret quarterly and annual financial data, defines key metrics like YOY, and highlights important figures such as revenue, gross profit, operating profit, and EPS for stock analysis. …

Bionano's Q2 Results Webcast Will Stay Online for at Least 30 Days

NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

Bionano Genomics Inc (BNGO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Bionano Genomics Inc (BNGO). It indicates that BNGO has not distributed any dividends in the past five years but lists several stock split events, including a 60-to-1 merger on January 22, 2025, and …

Bionano Genomics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Bionano Genomics Inc (BNGO), a company specializing in genome analysis solutions. It outlines their business scope, including optical genome mapping (OGM) and platform-agnostic software, and provides financial data points like market capitalization and revenue breakdown. The article …

Bionano Genomics Inc (BNGO) Earnings Date & Reports & Earnings News

Bionano Genomics Inc (BNGO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Bionano Genomics Inc (BNGO) shareholder structure, detailing major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and presents a historical view of institutional shareholdings and recent changes in activity.

TradingKey

This article provides a detailed cash flow statement for Metagenomi Inc (MGX), including operating, investing, and financing cash flows, presented quarterly and annually. It includes multi-year financial data, percentage changes, and a FAQ section clarifying financial terms like operating cash flow, investing cash flow, …

Metagenomi Inc (MGX) Balance Sheet Analysis

This article provides a detailed quarterly and annual balance sheet analysis for Metagenomi Inc (MGX). It presents key financial metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal quarters. The content also includes an FAQ section addressing important balance sheet metrics …

Bionano Genomics, Inc. Revenue Breakdown – BMV:BNGO

Bionano Genomics, Inc. (BMV:BNGO) generated 513.94 million MXN in revenue last year. The "Consumables" segment was its top-performing segment, contributing 251.85 million MXN, though this was down from the previous year's 266.31 million MXN. Geographically, EMEA was the largest contributor, accounting for 254.34 million …

Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Raises Target Price to $16

Benchmark Co. has reiterated its Buy rating on NeoGenomics (NEO.US) and increased its price target to $16. This adjustment reflects the firm's continued confidence in the company's prospects.

MGX|Metagenomi Inc|Price:1.200|Chg%:-0.020

Metagenomi Inc. (MGX) is a precision genetic medicine company focused on developing curative therapeutics using its comprehensive metagenomics-derived toolbox, including programmable nucleases and CRISPR-associated transposases. The company employs AI and its metagenomics platform to create genetic medicines. As of Q1 2026, 172 institutions hold …

NEO Maintained by Benchmark -- Price Target Raised to $16.00

Benchmark maintained a Buy rating on NeoGenomics (NEO) and raised its price target to $16.00, up from the previous $11.00. GuruFocus indicates that NEO is currently undervalued by 14.7% with a GF Value™ of $16.69 and holds a solid GF Score™ of 72/100, though …

NeoGenomics Inc. (NG9) Q2 2025 Earnings Report - Results, Call & Slides

NeoGenomics Inc. (NG9) released its Q2 2025 earnings report, indicating a beat on EPS with €0.03 against a consensus of €0.02, but missed revenue expectations at €159.26M versus an anticipated €160.42M. The company experienced a 10.23% year-over-year revenue growth. The earnings call was scheduled …

NeoGenomics, Inc. Files 8-K Report on July 20, 2026 – Key Corporate and Financial Disclosure Details

NeoGenomics, Inc. (NASDAQ: NEO) has finalized a civil settlement with the U.S. Department of Justice for $9,813,260, resolving an investigation into consulting services. The settlement amount is less than the $11.2 million reserve previously accrued by the company, suggesting a positive financial outcome. This …

NeoGenomics (NEO) to Post Quarterly Earnings on Tuesday

NEOGENOMICS INC 8-K — Jul 20, 2026

This article reports on an 8-K filing by NEOGENOMICS INC on July 20, 2026. It highlights that the filing includes "Other events (+2 more items)". The financial document is available for viewing on SEC.gov.

NeoGenomics Settles DOJ Investigation Related to Laboratory Collaboration Program

NeoGenomics, Inc. announced a settlement with the U.S. Department of Justice (DOJ) regarding an investigation into its laboratory collaboration program. The settlement will result in a payment of $30 million by NeoGenomics, resolving claims related to potential False Claims Act violations. While the company …

NeoGenomics finalizes $9.81M DOJ settlement over voluntary OIG-HHS disclosure

NeoGenomics has finalized a civil settlement with the Department of Justice on behalf of OIG-HHS, agreeing to pay $9,813,260 plus interest to resolve an investigation into certain consulting services related to its Laboratory Collaboration Initiative. The company self-disclosed the issue in November 2021 and …

NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation

NeoGenomics has agreed to pay $9.8 million to settle allegations from the U.S. Justice Department that it violated the False Claims Act. The allegations center on the company providing laboratory consulting services below fair market value and paying referral-based compensation to independent consultants, which …

Cathie Wood Dumps $39 Million Worth of AMD Stock

This article first appeared on GuruFocus. Cathie Wood's ARK Invest reduced its position in Advanced Micro Devices (NASDAQ:AMD) during the week ended July 17, making the chipmaker its largest sale of the period. ARK sold approximately $39.2 million of AMD shares as part of …

(NEO) Volatility Zones as Tactical Triggers

This article analyzes Neogenomics Inc. (NYSE: NEO) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe …

Metagenomi Therapeutics (MGX) Proxy filing Summary

Metagenomi Therapeutics (MGX) held its annual meeting virtually on June 9, 2026, where shareholders voted on the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The board recommended voting for both proposals. The company …

NeoGenomics (NEO) Stock Looks Above Fair Value After A 134% Run

NeoGenomics (NEO) stock has seen a significant 134.1% return over the past year, but current evaluations suggest it may be overvalued. The company's P/S ratio of 2.6x is significantly higher than the Healthcare industry average of 1.5x, implying the market is pricing in a …

Metagenomi Therapeutics (MGX) Q1 2026 earnings summary

Metagenomi Therapeutics (MGX) reported Q1 2026 earnings, focusing on its in vivo genome editing pipeline and a strategic reprioritization of its lead programs. The company's lead program, MGX-001 for hemophilia A, showed promising preclinical data with an IND submission planned for Q4 2026. Financial …